• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[黑色素瘤:影像学介绍及特殊要求]

[Melanoma: introduction and special demands on radiology].

作者信息

Schiller M, Hassel J C

机构信息

Universitätshautklinik, Nationales Centrum für Tumorerkrankungen, Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland.

出版信息

Radiologe. 2015 Feb;55(2):93-8. doi: 10.1007/s00117-014-2758-8.

DOI:10.1007/s00117-014-2758-8
PMID:25609505
Abstract

CLINICAL ISSUE

The incidence of melanoma has rapidly increased in the last decades. Most relevant for patient prognosis is the tumor thickness, hence an early diagnosis is crucial.

STANDARD TREATMENT

The basis of treatment is at the primary tumor stage and excision of regional metastases with curative intention.

TREATMENT INNOVATIONS

Targeted therapies, such as BRAF and MEK inhibitors have the advantage of a rapid response even in highly advanced stages of the disease.

DIAGNOSTIC WORK-UP: For routine diagnostics ultrasound, computed tomography (CT), fluorodeoxyglucose positron emission tomography CT (FDG-PET/CT) and magnetic resonance imaging (MRI) are used.

PERFORMANCE AND ACHIEVEMENTS

In the treatment of distant metastases new treatment options are available which more than doubled patient survival rates. Especially immune therapies with immune checkpoint blockers, such as ipilimumab or PD-1 antibodies can lead to long-term survival of patients. In contrast to chemotherapy these new substances have characteristics which make new demands on radiologists related to the possibility of pseudoprogression in immune therapies, which make it necessary to use other response criteria. In addition, autoimmune phenomena, such as a sarcoid-like reactions may mimic new metastases and should be included in the differential diagnosis. BRAF inhibitors may lead to cystic conversions of metastases which again require an evaluation beyond the response evaluation criteria in solid tumors (RECIST), e.g. with the adapted Choi criteria.

PRACTICAL RECOMMENDATIONS

Close interdisciplinary communication, functional imaging methods and adapted response criteria, such as the immune-related response criteria will optimize radiological evaluations of melanoma.

摘要

临床问题

在过去几十年中,黑色素瘤的发病率迅速上升。对患者预后最相关的是肿瘤厚度,因此早期诊断至关重要。

标准治疗

治疗的基础是在原发性肿瘤阶段,以治愈为目的切除区域转移灶。

治疗创新

靶向治疗,如BRAF和MEK抑制剂,即使在疾病的高度进展阶段也具有快速反应的优势。

诊断检查

常规诊断使用超声、计算机断层扫描(CT)、氟脱氧葡萄糖正电子发射断层扫描CT(FDG-PET/CT)和磁共振成像(MRI)。

性能与成就

在远处转移的治疗中,有新的治疗选择,患者生存率提高了一倍多。特别是使用免疫检查点阻断剂的免疫疗法,如伊匹单抗或PD-1抗体,可使患者长期存活。与化疗不同,这些新物质具有一些特性,对放射科医生提出了新的要求,因为免疫疗法中可能出现假性进展,这就需要使用其他反应标准。此外,自身免疫现象,如结节样反应,可能会模仿新的转移灶,应纳入鉴别诊断。BRAF抑制剂可能导致转移灶的囊性转化,这同样需要超出实体瘤反应评估标准(RECIST)的评估,例如采用改良的Choi标准。

实用建议

密切的多学科沟通、功能成像方法和适应性反应标准,如免疫相关反应标准,将优化黑色素瘤的放射学评估。

相似文献

1
[Melanoma: introduction and special demands on radiology].[黑色素瘤:影像学介绍及特殊要求]
Radiologe. 2015 Feb;55(2):93-8. doi: 10.1007/s00117-014-2758-8.
2
Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST.接受 BRAF 抑制剂治疗的转移性黑色素瘤患者的治疗反应评估:适应性 Choi 标准比 RECIST 标准能更好地反映早期治疗反应。
Acad Radiol. 2013 Apr;20(4):423-9. doi: 10.1016/j.acra.2012.09.029.
3
[Treatment side effects and follow-up of malignant melanoma].[恶性黑色素瘤的治疗副作用及随访]
Radiologe. 2015 Feb;55(2):136-43. doi: 10.1007/s00117-014-2764-x.
4
[Systemic treatment of inoperable metastasized malignant melanoma].[无法手术的转移性恶性黑色素瘤的全身治疗]
Hautarzt. 2016 Jul;67(7):529-35. doi: 10.1007/s00105-016-3795-1.
5
[Response criteria for malignant melanoma: RECIST and irRC].[恶性黑色素瘤的疗效评估标准:RECIST 和 irRC]
Radiologe. 2015 Feb;55(2):127-35. doi: 10.1007/s00117-014-2763-y.
6
(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.(18)F-FDG PET/CT 与黑色素瘤:分期、免疫调节与突变靶向治疗评估及预后
AJR Am J Roentgenol. 2015 Aug;205(2):259-70. doi: 10.2214/AJR.14.13575.
7
[Malignant melanoma : Current status].[恶性黑色素瘤:现状]
Radiologe. 2017 Oct;57(10):814-821. doi: 10.1007/s00117-017-0281-4.
8
[The latest diagnostical methods and therapy in melanoma].[黑色素瘤的最新诊断方法与治疗]
Przegl Lek. 2006;63(8):674-80.
9
Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.BRAF 突变转移性黑色素瘤患者早期 18F-FDG PET/CT 对 BRAF 和 MEK 抑制的反应与生存之间的相关性
Nucl Med Commun. 2016 Feb;37(2):122-8. doi: 10.1097/MNM.0000000000000406.
10
Survival of patients with advanced metastatic melanoma: The impact of novel therapies.晚期转移性黑色素瘤患者的生存情况:新型疗法的影响
Eur J Cancer. 2016 Jan;53:125-34. doi: 10.1016/j.ejca.2015.09.013. Epub 2015 Dec 17.

引用本文的文献

1
Immune checkpoint inhibitors and response analysis: a tough challenge. A case report.免疫检查点抑制剂与反应分析:一项严峻挑战。病例报告。
BMC Res Notes. 2016 Jul 18;9:349. doi: 10.1186/s13104-016-2153-9.

本文引用的文献

1
Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.18F-FDG PET/CT 早期研究对伊匹单抗治疗转移性黑色素瘤的疗效评估的预测价值:一项正在进行的研究的初步结果。
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96. doi: 10.1007/s00259-014-2944-y. Epub 2014 Oct 31.
2
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.转移性黑色素瘤中 RAF 抑制临床耐药的遗传特征。
Cancer Discov. 2014 Jan;4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617. Epub 2013 Nov 21.
3
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
CTLA-4 和 PD-1/PD-L1 阻断:黑色素瘤患者具有持久临床获益的新免疫治疗方式。
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143.
4
Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST.接受 BRAF 抑制剂治疗的转移性黑色素瘤患者的治疗反应评估:适应性 Choi 标准比 RECIST 标准能更好地反映早期治疗反应。
Acad Radiol. 2013 Apr;20(4):423-9. doi: 10.1016/j.acra.2012.09.029.
5
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.BRAF V600 突变型黑色素瘤的联合 BRAF 和 MEK 抑制治疗。
N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.
6
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.达拉非尼治疗 BRAF 突变型转移性黑色素瘤:一项多中心、开放标签、III 期随机对照临床试验。
Lancet. 2012 Jul 28;380(9839):358-65. doi: 10.1016/S0140-6736(12)60868-X. Epub 2012 Jun 25.
7
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.接受完全缓解的转移性黑色素瘤患者发生伊匹单抗诱导的结节病。
J Clin Oncol. 2012 Jan 10;30(2):e7-e10. doi: 10.1200/JCO.2011.37.9693. Epub 2011 Nov 28.
8
Systematic skin cancer screening in Northern Germany.在德国北部进行系统性皮肤癌筛查。
J Am Acad Dermatol. 2012 Feb;66(2):201-11. doi: 10.1016/j.jaad.2010.11.016. Epub 2011 Nov 8.
9
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.甲磺酸伊马替尼治疗伴有 c-Kit 突变或扩增的转移性黑色素瘤患者的 II 期、开放标签、单臂试验。
J Clin Oncol. 2011 Jul 20;29(21):2904-9. doi: 10.1200/JCO.2010.33.9275. Epub 2011 Jun 20.
10
KIT as a therapeutic target in metastatic melanoma.KIT 作为转移性黑色素瘤的治疗靶点。
JAMA. 2011 Jun 8;305(22):2327-34. doi: 10.1001/jama.2011.746.